Overview

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed Condition

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Objective: Primary objective of the present study was to compare the single dose bioavailability of Torrent's Felodipine Extended-Release Tablets USP 10 mg and Innovator's (Mylan Pharmaceuticals Inc., USA) Felodipine Extended-Release Tablets USP 10 mg. Dosing periods were separated by a washout period of 21 days during fasting study. Study Design: Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study
Phase:
Phase 1
Details
Lead Sponsor:
Torrent Pharmaceuticals Limited
Treatments:
Felodipine